MwanzoPTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Bei iliyotangulia
$ 14.64
Bei za siku
$ 14.46 - $ 14.46
Bei za mwaka
$ 11.44 - $ 21.16
Thamani ya kampuni katika soko
56.64T IDR
Wastani wa hisa zilizouzwa
85.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (IDR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 8.91T | 12.62% |
Matumizi ya uendeshaji wa biashara | 2.60T | 14.02% |
Mapato halisi | 656.41B | 14.50% |
Kiwango cha faida halisi | 7.37 | 1.66% |
Mapato kwa kila hisa | 14.44 | 16.36% |
EBITDA | 1.05T | 16.48% |
Asilimia ya kodi ya mapato | 24.06% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (IDR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 4.20T | -2.69% |
Jumla ya mali | 30.10T | 4.70% |
Jumla ya dhima | 5.30T | 9.51% |
Jumla ya hisa | 24.80T | — |
hisa zilizosalia | 45.32B | — |
Uwiano wa bei na thamani | 0.03 | — |
Faida inayotokana na mali | 7.14% | — |
Faida inayotokana mtaji | 8.47% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (IDR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 656.41B | 14.50% |
Pesa kutokana na shughuli | 875.16B | -24.23% |
Pesa kutokana na uwekezaji | -258.39B | -46.28% |
Pesa kutokana na ufadhili | -396.06B | 5.95% |
Mabadiliko halisi ya pesa taslimu | 245.07B | -49.14% |
Mtiririko huru wa pesa | 569.54B | -24.75% |
Kuhusu
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Ilianzishwa
10 Sep 1966
Tovuti
Wafanyakazi
12,784
